AP-FILE #236B: PROJECT "SEMIDEUS" (S-SOLDIER)

[The Core]

AP-FILE #236B: PROJECT "SEMIDEUS"

• OBJECTIVE: Conduct research into breeding genetically engineered high efficient soldiers
• ASSIGNED APM PERSONNEL: Prof. W. Breen, Prof. I. Kleiner
• AUDIT: Dr. J. Engele, CEO M.McKinsey
• STATUS: Incomplete

Brief

---

While bionic augmentation has proven to effectively increase combat abilities of the human body, their development and maintenance remain relatively cost-intensive. To meet the demand of a combat efficient yet expendable security force a separate research program has been launched - not as substitution of the latter, but as an alongside developed alternative.

Under highest security protocols deep within Alabama Shipyard, the most gifted minds devote their life's work to outline methods of breeding the perfect soldiers for The Core's own security applications, as well as outside distribution to clients who seek a numerous, obedient, expendable force.

Progress

---

Thus far several prototypes have been developed, some of the designs yield high promises. However, scientists still struggle with durability issues resulting from enhanced growth and/or frequent mental dysfunctions.

Nota bene: the project agenda does not consider any of the experimental developments as "human" per se.

APM audit advises that further related projects on non-bionic, transplantational or pharmaceutical feature enhancement be launched to draw additional data which may contribute to the progress of the experiment.

On hand of the data gathered thus far, project management has outlined the following objectives to current research with the ultimate goal of producing a satisfactory performing prototype:

1. DNA mapping - incomplete. The final genetic combination of the model is to guarantee highest possible quality of replication with a protein degeneration rate of no more then 0,079% per breed and unitary wellformedness of no less then 91% per breed. Each genetic matrix is estimated for up to 10 reproductions to ensure proper structural quality of the replicant.

2. Memory programming - incomplete. For a replicant to show desired mental performance, including such features as obedience, trauma resistance, proper logic and stable composure, it is vital to equip each model with a generic set of memories, which combined form a normative model of consciousness.

3. Production refinement - incomplete. Although the growth process utilized so far has proven sufficient, APM audit indicates that it does not fulfill cost efficiency standards for mass production. Further development is required.

---

[Docent]

---

---

:::[INCOMING TRANSMISSION]:::
:::[ESTABLISHING VIDEO FEED]:::
:::[VIDEO FEED: Live]:::

ID: Martin McKinsey
Location: Alabama Shipyard, Omicron Rho
Subject: Audit
ENCRYPTION: APM-STANDARD

---

---

Audit recognizes the lucrative potential of this project in the long run. Current prospects however are in favor of short term projects which promise faster returns. For the time being "Semideus" will be kept up with minimal funding until other goals are reached or other circumstances lead to redistribution of priorities.


-M.McKinsey
CEO, AP Manufacturing

---

---

:::[CLOSING TRANSMISSION]:::

---

---

[Docent]

---

:::[OPENING LOG]:::
:::[SEARCHING FOR VIDEO FEED]:::
:::[VIDEO FEED: STREAMING]:::

»ID: Martin McKinsey
»Location: APM Flagship "Core|APM-Sagittarius-FS"
»Subject: PROJECT "SEMIDEUS"
»ENCRYPTION: APM-STANDARD

---

Memo:

Of the prototype replicants developed before priorities shifted, 7 were now chosen to be tested in the field. Naturally, we do not wish to let the funding spent on the project thus far go to waste - it is to be put to work as soon as possible instead. High Command composed a special operations strike wing tagged Core|7 which utilizes the most promising breed.

Though I am overly in favor of not letting the tens of millions already spent on this project dwell idly, I voice my concerns in regard to the certain mental dysfunctions, including paranoia and severe psychosis that have been the result of yet imperfect processes, viz. DNA mapping and memory programming, which both contribute to the present condition. The Core|7 is therefore considered a high risk endeavor despite pharmacological suppression.

-M.McKinsey
CEO, AP Manufacturing

---

:::[END ENTRY]:::

---